Please login to the form below

Not currently logged in
Email:
Password:

Combination treatment

This page shows the latest Combination treatment news and features for those working in and with pharma, biotech and healthcare.

Lilly asks to revoke emergency authorisation for bamlanivimab monotherapy in the US

Lilly asks to revoke emergency authorisation for bamlanivimab monotherapy in the US

Across the study population, which included 1, 035 patients, there were 11 events in patients receiving Lilly’s antibody combination treatment, while 36 events occurred in the placebo group. ... The antibody combination treatment also demonstrated

Latest news

More from news
Approximately 0 fully matching, plus 301 partially matching documents found.

Latest Intelligence

  • As COVID-19 takes over the world, biopharma fights back As COVID-19 takes over the world, biopharma fights back

    A combination HIV treatment: AbbVie’s Kaletra. In an unprecedented move, AbbVie has suspended its patents on its combination HIV drug Kaletra, after it was identified as having potential against ... The combination drug was first included in Chinese

  • Deal Watch April 2016 Deal Watch April 2016

    Another deal worth pondering about is the $265m exclusive license by AstraZeneca (AZ) of the approved Zurampic (lesuranid) plus a fixed dose combination with allopurinol for treatment of gout. ... 85 . Dong A (SK). Tobira (US). Cross license. Evogliptin

  • Pharma deals in April 2015 Pharma deals in April 2015

    No deal terms were disclosed. The initial development plan will look at the combination therapy as a potential treatment for NHL.  . ... The treatment combines an antibody engineered to target CD19 with the cancer-killing agent maytansinoid.

  • Pharma deals during July 2014 Pharma deals during July 2014

    Underscoring its strategy in focusing the business in the core areas, in July Baxter also announced the acquisition of AesRx, a private US company developing a phase II stage prophylactic treatment ... The acquisition of Almirall's respiratory business

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    And again, matching drugs that work well together will be crucial going forward: “Combination treatment will be a critical component; how best to put these drugs together with other checkpoint inhibitors, ... This includes people with NSCLC who have a

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

  • Oncosec

    body.  OncoSec has built a deep and diverse clinical pipeline utilizing TAVO as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; ... Results from recently completed

  • Marketing strategy in complex environments

    The last few years have seen influential scientific advances, resulting in subtle shifts in how pharma tackles disease treatment. ... The treatment of aggressive diseases often benefits very noticeably from combination therapy, especially when involving

More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics